APOLLOMICS INC
APLMNASDAQTrading Snapshot
- Day Range
- $19.65 – $19.65
- 52-Week Range
- $10.01 – $28.29
- Volume (shares)
- 219
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.9M
- Next Earnings
- 2027-04-01
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- —
- P/E Ratio
- -2.6
- P/S Ratio
- 6.8x
- EPS (TTM)
- $-25.98
- Dividend Yield
- 0.00%
APOLLOMICS INC
APLMFinancial history unavailable.
StockOtter · stockotter.spaceAbout APOLLOMICS INC
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.